The role of allogeneic stem cell transplantation in multiple myeloma in the new drug era
|
|
- Evangeline Cole
- 8 years ago
- Views:
Transcription
1 DCTH The role of allogeneic stem cell transplantation in multiple myeloma in the new drug era N. Kröger Department for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Germany SUMMARY Multiple myeloma is considered to be an incurable disease. Despite the introduction of autologous stem cell transplantation and more recently novel agents, such as lenalidomide and bortezomib, still induces the highest rate of clinical complete and molecular remission and it can induce long-term freedom from disease in about 30-40% of the cases. The major disadvantage is the higher morbidity and mortality of this approach, which are caused by immunological complications after transplantation such as graft-versushost disease and infectious diseases. However, donor derived T-cells and may also NK cells can also induce a graft versus myeloma effect. This graft versus tumor effect seems to be less strong than in other hematological diseases, but donor-lymphocyte infusions given to patients who relapsed after allogeneic stem cell transplantation can induce response rate between 40% and 67%. Allogeneic stem cell therapy studies suggest that achievement of molecular remission after transplantation is associated with long-term freedom from disease. Modern myeloma therapy approaches should lower the therapy related mortality of allogeneic stem cell transplantation and use this immunological platform for immunological-or drug based therapies post transplantation to achieve molecular remission and ultimately cure. Key words: graft-versus-myeloma effect,, multiple myeloma, reduced intensity conditioning, unrelated donor. Correspondence: Nicolaus Kröger Department of Stem Cell Transplantation University Hospital Hamburg-Eppendorf Martinistrasse, Hamburg, Germany nkroeger@uke.uni-hamburg.de INTRODUCTION Compared with other treatment modalities in multiple myeloma, allogeneic stem cell transplantation induces the highest rate of clinical complete and molecular remission (1, 2), and it can induce long-term freedom from disease in about 30-40% of the cases (3-7). Despite the recent improvement in performing allogeneic stem cell procedure (8), it is still the treatment
2 60 N. Kröger modality with the highest treatmentrelated morbidity and mortality. Both morbidity and mortality are related to organ toxicity induced by the conditioning regimen and to immunological complications after transplantation such as graft-versus-host disease and infectious diseases. Evidence of a strong immunologically mediated antimyeloma effect came from donorlymphocyte infusions given to patients who relapsed after allogeneic stem cell transplantation. Response rate (CR/PR) between 40% and 67% can be achieved but only in a minority of patients these remissions are durable (9, 10). INTENSITY OF THE CONDITIONING REGIMEN Since the toxicity of the conditioning regimen prior to allogeneic stem cell transplantation contributes to treatment-related morbidity and mortality, a strategy to reduce treatment-related mortality by reducing the toxicity of the conditioning regimen by either toxicity - or dose - reduced regimens has been investigated. Since low-intensity-conditioning approach, which is mainly focused on immuno-competent donor-t-cells, is not sufficient to control advanced disease in myeloma patients (11) it became clear that further effective cytoreductive treatment might be necessary, especially since it became obvious that there is a positive correlation between higher CR rate as well as higher treatmentrelated mortality and the intensity of the conditioning regimen. This is in accordance with a retrospective comparison from the European Group for Blood and Marrow Transplantation (EBMT) reporting a higher CR-rate for myeloablative conditioning in comparison to reduced intensity conditioning (53% vs 34%, P<0.001) (12). There are also more reports suggesting that standard myeloablative conditioning has improved in time, especially with respect to treatment-related mortality. The Myeloma Subcommittee of EBMT reported a better survival for myeloma patients transplanted after 1994 in comparison to those who received an allograft before 1994 (overall survival at three years: 56% vs 35%) (8). This major improvement is due to a marked reduction in treatment-related mortality (30% vs 46%) probably due to better patient selection and improved supportive care. More recently, smaller phase II studies using myeloablative conditioning reported TRM rates of less than 20% suggesting only marginal difference in TRM between myeloablative and reduced-intensity conditioning (5-7). However, the medium age of the patients treated with standard conditioning were about ten years younger in comparison to those treated with reduced-intensity conditioning. The already above-mentioned study of the Myeloma Subcommittee of the EBMT comparing a reduced-intensity conditioning (n=320) with myeloablative conditioning (n=196) showed a reduced non-relapse mortality for RIC transplantation (24% vs 37%, P=0.002), but a lower progression-free survival (19% vs 35%, P=0.001) and no statistical difference in overall survival (38% vs 51%, n.s.). On multivariate analysis RIC was associated with lower non-relapse mortality (HR: 0.5) but a higher risk of re-
3 The role of in multiple myeloma in the new drug era 61 lapse (HR: 2.0) (12). A more recent performed study using busulfan/cyclophosphamide based toxicity reduced myeloablative conditioning regimen resulted in only 6% non-relapse mortality in advanced myeloma patients who relapsed to an autograft (13). COMBINING AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION To maintain the efficacy of intensive chemotherapy, the concept of autologous-allogeneic-tandem transplantation was introduced (14). In this treatment concept, high-dose chemotherapy and adoptive immunotherapy by immuno-competent donor-t-cells were splitted within an interval of two to three months in order to lower toxicity and treatment-related mortality but maintain high-dose chemotherapy as well as the immuno-mediated graftversus-myeloma effect (14-17). The randomized IFM99 protocol comparing auto-allo tandem approach with tandem autologous stem cell transplantation in high-risk patients could not show any benefit for the auto-allo approach. This could be due to the very-high-risk group of patients included or, more likely, to the use of high-dose anti-thymocyte-globulin (12.5 mg/kg Thymoglobulin ), which might have offset the graft-versus-myeloma effect by profound T-cell depletion. This randomized study did not show any significant difference in event-free and overall survival between the auto-allo- and the tandem-auto-arm after a median follow-up of 24 months (17). The Italian study group compared 54 patients with multiple myeloma who received autoallo-tandem transplantation from HLAidentical sibling and compared the results with 54 patients who receive tandem-autologous stem cell transplantation within the same time period (15). They reported a higher CR rate (54% vs 26%) and an improved progressionfree (75% vs. 41%, P<0.001) and overall survival (84% vs 62%, P=0.006) for patients who received an allograft. The BMT CTN study reported results after a relative short follow up of 36 months. At this time results were 77% OS and 43% PFS with auto RICallo and 80% OS and 46% PFS with auto/auto in the BMT CTN study. The non-relapsed mortality was 11% with the auto/ricallo procedure and 3% with auto/auto respectively (18). The HOVON study (19) had a somewhat different approach using conditioning with TBI 2Gy without fludarabine and maintenance therapy with thalidomide in some of the auto patients. OS at 6 years was 55% in patients with or without a donor. PFS at 6 years was 28% in patients with a donor, compared to 22% without a donor in the HOVON study. Although not significant in the HOVON study, there was a trend for a lower relapse/ progression rate in the auto/ RICallo arm. It has to be taken into account that the auto patients received maintenance treatment with thalidomide contrary to the allo arm. In the EBMT trial which used also 2 Gy TBI/fludaraine in the allo arm the PFS and OS at 60 months was significantly higher in the auto-allo arm (35% and 65%) in comparison to auto transplantation (18% and 58%). The same was true for the achievement of complete remission (51% vs 41%, P=0.02) (20).
4 62 N. Kröger REDUCING RISK OF RELAPSE Despite the obvious graft versus myeloma effect the risk of relapse is substantial and is the major cause of treatment failure after allogeneic stem cell transplantation in myeloma patients. Several investigators have showed the importance of achieving complete remission on duration of event-free survival after autologous stem cell transplantation (21). Complete remission in patients with multiple myeloma is defined by negative immunofixation. However, the sensitivity of immunofixation to detect residual disease is low. Since residual disease is associated with relapse risk, more sensitive methods to detect residual disease in myeloma patients have been investigated. The most sensitive method is based on clonal markers derived from the re-arrangement of immu noglobulin heavy-chain genes, which have to be generated from each patient at diagnosis. Using these patient-specific primers, residual myeloma cells can be detected by polymerase-chain reaction (PCR) with a sensitivity of 10 4 to 10 6 (1, 2). Molecular remissions are seen more often after allogeneic than after autologous stem cell trans plantation. In patients who achieved clinical complete remission, nine out of 14 allograft-patients, but only two out of 15 autograftpatients entered molecular remission. It is of interest that molecular remission after allografting occurred in some patients more than three years after transplantation (1). The importance of achieving molecular remission for long-term disease freedom has been shown for myeloablative in a retrospective EBMT-study (22). In this study using high sensitive patientspecific primers to monitor residual disease with PCR-technique, it could be shown that durable PCR-negativity after allografting had a cumulative risk of relapse at five years of 0%, in comparison to 33% for PCR-mixed patients and 100% for patients who never achieved PCR-negativity. More recently using auto-allo tandem approach molecular remission could be achieved in 41% of the patients and was sustained in 21% of the patients. The progression-free and overall survival correlated well with the depth of remission and for those with sustained molecular remission the 5 year PFS was 85%, which included also high risk patients defined by del17q or t(4;14) (23). POST-TRANSPLANT STRATEGIES The importance of molecular remission on long-term freedom of disease has been mentioned above. Therefore, post-transplant strategies either as maintenance therapy or better to improve remission status are of clinical importance. After autologous stem cell transplantation, therapy with thalidomide given as maintenance therapy resulted in an improved event-free and overall survival (24). Despite the high risk of relapse after allografting, there are only few reports about posttransplant strategies after allogeneic stem cell transplantation in multiple myeloma in the literature. The commonly used adoptive immunotherapy after is donor-lymphocyte infusion (DLI) (25). In multiple myeloma in most reports DLI was given for relapse (9, 10,
5 The role of in multiple myeloma in the new drug era ), and only few reported about prophylactic DLI (30-32). Response rates be tween 40% and 67% were reported but in some studies additional chemotherapy or interferon-a were given (9, 10). Nearly 30% of the patients achieved complete remission, and response to DLI was correlated for occurrence and severity of acute graft-versus-host disease (GvHD). The inci dence of acute GvHD ranges between 52% and 56% and of chronic GvHD between 26% and 44% (9, 10). DLI given after reduced intensity conditioning in a dose escalating way resulted in less acute and chronic GvHD (29, 31). In a European survey, the effect of DLI after reduced-intensity conditioning was investigated in patients with relapse (n=48) or persistent disease (n=15) after allograft. Nineteen percent of the patients achieved partial remission, and 19% complete remission (33). The median time to progres sion was seven months for patients with partial remission, and 28 months for patients who achieved complete remission. To enhance the anti-myeloma effect of DLI after allografting, low-dose thalidomide (100 mg) in combination with DLI was investigated. The overall response rate was 67% with 22% complete remission. Interestingly, no grade II-IV acute GvHD was seen, and only a small minority developed limited chronic GvHD (34). Other new drugs such as the proteasome-inhibitor bortezomib might have a major role after since it could be shown in preclinical mice models that proteasome-inhibition inhibits T-cell proliferation and acute GvHD with retaining the graftversus-tumor effect (35). In a clinical study investigating bortezomib as post-transplant treatment to enhance remission status, a complete or partial remission could be induced in 30% and 50%, respectively (36). Even in patients refractory to DLI, salvage treatment with thalidomide or bortezomib can induce complete or partial remission in 83% of the cases (37). Another aim to improve the results in allografting of myeloma patients is the introduction of lenalidomide post transplant. Lenalidomide maintenance therapy which started at a median of 168 days after transplantation induces some toxicity which was mainly GvHD-related. 28% of the patients experienced grade II-III acute GvHD after lenalidomide, and a previous dose-finding study has shown an increase of NK cytotoxicity but also an early increase of interferon gamma secreting T-cells (38). In a similar study by the HOVON group investigating 10 mg lenalidomide after for myeloma patients, 37% developed acute GvHD (39). Other toxicities were myelosuppression and fatigue and according to the recently published dose-finding study the starting dose should not exceed 5 mg. Nevertheless due to the described toxicity, about 50% of the patients had to discontinue the lenalidomide treatment periodically or permanently. Even if the true value of lenalidomide post allograft cannot be determined from the design of the current study the relative long progression-free survival of 52% at 3 years is higher than the reported 3 year PFS in similar allogeneic studies without lenalidomide. Further improvement of immunologically based strategies post-allo-trans-
6 64 N. Kröger plant lies in the separation of the graftversus-myeloma effect from the graftversus-host reaction, which would allow a more specific tumor-targeting without or lesser risk of GvHD. Potential candidates for a more specific T-cell response are minor histocompatibility antigens such as HA-1. HA-1 specific T- cells could be generated and induced complete remission in a patient with relapsed multiple myeloma after allogeneic stem cell transplantation (40). Another potential target is cancertestis-antigens, especially MAGEC2 or MAGEA3 which are expressed in more than 50% of myeloma cells (41). More recently activated donor KIR genes may be protective against relapse, suggesting a potential role of alloreactive NK-cells after allografting to enhance remission status and prevent relapse (42). Overall post-transplant immunotherapy with DLI and novel agents can upgrade remission into molecular remission (43). Acknowledgements: we thank the staff of the BMT unit for providing excellent care of our patients and the medical technicians for their excellent work in the BMT laboratory. This work was supported by a grant from the Deutsche Krebsgesellschaft e.v., the Deutsche José Carreras Leukämie-Stiftung e.v., and the Wilhelm Sander-Stiftung. REFERENCES 1. Corradini P, Voena C, Tarella C, et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000; 18: Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: Hunter HM, Peggs K, Powles R, et al. Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT). Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning - evidence for a superior outcome using melphalan combined with total body irradiation. Br J Haematol 2005; 128: Kröger N, Einsele H, Wolff D, et al. German Study-group Multiple Myeloma (DSMM). Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplant 2003; 31: Rabitsch W, Prinz E, Ackermann J, et al. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation. Eur J Haematol 2004; 72: Majolino I, Corradini P, Scime R, et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: Gahrton G, Svensson H, Cavo M, et al. European Group for Blood and Marrow Transplantation. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed and at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113:
7 The role of in multiple myeloma in the new drug era Lokhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103: Salama M, Nevill T, Marcellus D, et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graftversus-tumor effects. Blood 2001; 97: Crawley C, Iacobelli S, Bjorkstrand B, et al. Reduced intensity conditioning for myeloma: lower non-relapse mortality but higher relapse rates compared to myeloablative conditioning. Blood 2007; 109: Kröger N, Zabelina T, Klyuchnikov E, et al. Toxicity-reduced, myeloablative allograft followed by lenalidomide as salvage therapy for refractory/relapsed myeloma patients. Bone Marrow Transplant 2012 Aug Kröger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation by dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: Maloney DG, Molina AJ, Sahebi F, et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in highrisk de novo multiple myeloma. Blood 2006; 107: Krishan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem cell transplantation followed by allogeneic or autologous haemopoietic stem cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011; 12: Lokhorst HM, van der Holt B, Cornelissen JJ, et al. Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study. Blood 2012; 119: Björkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reducedintensity conditioning allogeneic stemcell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol 2011; 29: O Shea D, Giles C, Terpos E, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: Corradini P, Cavo M, Lokhorst H, et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Trans plantation (EBMT). Molecular remission after myeloablative allogeneic stem cell trans plantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: Kröger N, Badbaran A, Zabelina T, et al. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2012 Oct Attal M, Harousseau JL, Leyvraz S, et al. (Intergroupe Francophone du Myelome). Maintenance therapy with thalidomide improves survival in patients
8 66 N. Kröger with multiple myeloma. Blood 2006; 108: Kolb HJ, Schattenberg A, Goldman JM, et al. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86 (5): Verdonck LF, van Blokland WT, Bosboom- Kalsbeek EK, et al. Complete donor T cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T cells. Bone Marrow Transplant 1996; 18: Bertz H, Burger JA, Kunzmann R, et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997; 11: Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: Ayuk F, Shimoni A, Nagler A, et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 2004; 18: Alyea E, Weller E, Schlossman R, et al. T- cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versusmyeloma effect. Blood 2001; 98: Peggs KS, Mackinnon S, Williams CD, et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapysensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9: Kroger N, Kruger W, Renges H, et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001; 112: van de Donk NW, Kroger N, Hegenbart U, et al. Prognostic factors for donor lymphocyte infusions following non-myeloablative in multiple myeloma. Bone Marrow Transplant 2006; 37: Kröger N, Shimoni A, Zagrivnaja M, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004; 104: Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versushost disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: Kroger N, Zabelina T, Ayuk F, et al. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: van de Donk NW, Kroger N, Hegenbart U, et al. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative in multiple myeloma. Blood 2006; 107: Wolschke C, Stübig T, Schonland S, et al. Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after. Exp Hematol 2012 Oct Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood 2011; 118: Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-
9 The role of in multiple myeloma in the new drug era 67 2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 2003; 100: Atanackovic D, Arfsten J, Cao Y, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 2007;109: Kröger N, Zabelina T, Berger J, et al. Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Leukemia 2011; 25: Kröger N, Badbaran A, Lioznov M, et al. Post-transplant immunotherapy with donor-lymphocyte infusions and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp Hematol 2009; 37:
Pro Cure in Multiple Myeloma. Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany
Pro Cure in Multiple Myeloma Nicolaus Kröger Dept. of Stem Cell Transplantation University Hospital Hamburg Hamburg, Germany Pro Cure in Multiple Myeloma Several hematological malignancies can be cured
More informationSTEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA Sundar Jagannath MD Professor of Medicine St. Vincent s Comprehensive Cancer Center New York, NY Where is transplant today in the management of Myeloma? Autologous
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationHematopoietic Stem-Cell Transplantation for Multiple Myeloma. Original Policy Date
MP.03.12 Hematopoietic Stem-Cell Transplantation for Multiple Myeloma Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013
More informationBiol Blood Marrow Transplant 19 (2013) 398e404
Biol Blood Marrow Transplant 19 (2013) 398e404 Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after AutologouseAllogeneic Tandem Transplantation
More informationHematopoietic Stem-Cell Transplantation for Multiple Myeloma
Hematopoietic Stem-Cell Transplantation for Multiple Myeloma Policy Number: Original Effective Date: MM.07.017 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 06/22/2012 Section: Transplants
More informationHematopoietic Stem-Cell Transplantation for Multiple Myeloma
Hematopoietic Stem-Cell Transplantation for Multiple Myeloma Policy Number: Original Effective Date: MM.07.017 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Transplants
More informationMedical Transplantation - The Best Place to Be Diagnosed With Kidney Cancer
DOI: 10.1093/annonc/mdf638 High-dose therapy in multiple myeloma J.-L. Harousseau Centre Hospitalier Universitaire, Service d Hématologie, Nantes, France Autologous stem cell transplantation The role of
More informationHow To Treat Multiple Myeloma With A Stem Cell Transplant
A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy Versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Nonmyeloablative Allogeneic
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationHematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome
Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome Policy Number: 8.01.17 Last Review: 3/2015 Origination: 12/2001 Next Review: 2/2016 Policy
More informationStem Cell Transplantation for Acute Lymphoblastic Leukemia
Stem Cell Transplantation for Acute Lymphoblastic Leukemia Mona Shafey MD, FRCPC Bone Marrow Transplant Fellow Alberta Blood and Marrow Transplant Program 1 of 14 Stem Cell Transplantation for Acute Lymphoblastic
More informationStem Cell Transplantation for Multiple Myeloma: Current and Future Status
CONTROVERSIES AND UPDATES IN MULTIPLE MYELOMA Stem Cell Transplantation for Multiple Myeloma: Current and Future Status Sergio Giralt 1 1 Memorial Sloan Kettering Cancer Center, New York, NY High-dose
More informationHematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
More informationFIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS
ORIGINAL ARTICLE FIFTEEN YEARS OF SINGLE CENTER EXPERIENCE WITH STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: A RETROSPECTIVE ANALYSIS Jakub Radocha, Vladimír Maisnar, Alžběta Zavřelová, Melanie Cermanová,
More informationHematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes
Hematopoietic Stem Cell Transplantation: Evolving Strategies That Have Resulted in Improved Outcomes Asad Bashey, MD, PhD Blood and Marrow Transplantation Program at Northside Hospital Atlanta, Georgia
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 10/1/2014 Most Recent Review Date (Revised): 6/2/2015 Effective Date: 8/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationHematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome
Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome Policy Number: Original Effective Date: MM.07.017 04/01/2008 Line(s) of Business: Current
More informationCure versus control: Which is the best strategy?
Cure versus control: Which is the best strategy? Barcelona 8-9-2012 Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY MULTIPLE MYELOMA Cure versus control
More informationTreatment results with Bortezomib in multiple myeloma
Treatment results with Bortezomib in multiple myeloma Prof. Dr. Orhan Sezer Hamburg University Medical Center Circulating proteasome levels are an independent prognostic factor in MM 1.0 Probability of
More informationHematopoietic Stem Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome
Hematopoietic Stem Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Policy Number: Original Effective Date: MM.07.017 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO
More informationHematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer
Hematopoietic Stem-Cell Transplantation for Epithelial Ovarian Cancer Policy Number: Original Effective Date: MM.07.014 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 01/23/2015 Section:
More informationRole of autologous and allogeneic stem cell transplantation in myeloma
Role of autologous and allogeneic stem cell transplantation in myeloma Author: William I. Bensinger, MD, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington. Corresponding
More informationChallenges of Hematopoietic Stem Cell Transplantation. Robert J. Soiffer, MD Dana Farber Cancer Institute
Challenges of Hematopoietic Stem Cell Transplantation Robert J. Soiffer, MD Dana Farber Cancer Institute Hematopoietic Stem Cell Transplantation Objectives Deliver sufficient chemo-radio therapy to destroy
More informationRole of allogeneic stem cell transplantation in relapsed or refractory Hodgkin s disease
Symposium article Annals of Oncology 13 (Supplement 1): 128 132, 2002 DOI: 10.1093/annonc/mdf626 Role of allogeneic stem cell transplantation in relapsed or refractory Hodgkin s disease A. Sureda 1 & N.
More informationMedical Policy Manual. Topic: Hematopoietic Stem-Cell Transplantation for Multiple Myeloma and POEMS Syndrome. Date of Origin: May 2010
Medical Policy Manual Topic: Hematopoietic Stem-Cell Transplantation for Multiple Myeloma and POEMS Syndrome Date of Origin: May 2010 Section: Transplant Last Reviewed Date: August 2015 Policy No: 45.22
More informationInfosheet. Allogeneic stem cell transplantation in myeloma. What is the principle behind stem cell transplantation?
Infosheet Allogeneic stem cell transplantation in myeloma High-dose therapy and autologous stem cell transplantation is currently the first-line treatment standard of care for younger/fitter myeloma patients.
More informationNATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
More informationHematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia
Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia Policy Number: Original Effective Date: MM.07.026 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO 04/26/2013 Section:
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationMEDICAL COVERAGE POLICY
Important note Even though this policy may indicate that a particular service or supply is considered covered, this conclusion is not necessarily based upon the terms of your particular benefit plan. Each
More informationReference: NHS England B04/P/a
Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationBendamustine for the fourth-line treatment of multiple myeloma
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for the fourth-line treatment of multiple myeloma Contents Summary 1 Background 2 Epidemiology 3 Cost 6 References 7 Summary There is no standard
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_plasma_cell_dyscrasias_multiple_myeloma
More informationMini-review Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts
(2001) 28, 725 735 2001 Nature Publishing Group All rights reserved 0268 3369/01 $15.00 www.nature.com/bmt Mini-review Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationFuture strategies for myeloma: An overview of novel treatments In development
Future strategies for myeloma: An overview of novel treatments In development Dr. Matthew Streetly Guys and St. Thomas NHS Trust How far have we come? Melphalan and prednisolone VAD Autologous SCT Thalidomide
More informationAUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE?
AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA: IS IT STILL THE RIGHT CHOICE? *Patrizia Tosi Hematology Unit, Department of Oncology and Hematology, Infermi Hospital, Rimini, Italy *Correspondence
More informationSelecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
More informationBone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Bone Marrow Transplantation
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationMULTIPLE MYELOMA (MM) is a chemotherapyrefractory
Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning By Ashraf Badros, Bart Barlogie, Eric Siegel, Michele Cottler-Fox, Maurizio Zangari,
More informationStem Cell Transplantation in Severe Aplastic Anemia
Stem Cell Transplantation in Severe Aplastic Anemia Dr. D. Goodyear MD, FRCPC Division of Hematology and Hematological Malignancies, University of Calgary 1 of 11 Introduction Most cases of aplastic anemia
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Bortezomib (Velcade) for Multiple Myeloma March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More information2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper
248 Ivyspring International Publisher Journal of Cancer 2014; 5(3): 248-252. doi: 10.7150/jca.8541 Research Paper Partial Response at Completion of Bortezomib- Thalidomide-Dexamethasone (VTd) Induction
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationOutline of thesis and future perspectives.
Outline of thesis and future perspectives. This thesis is divided into two different sections. The B- section involves reviews and studies on B- cell non- Hodgkin lymphoma [NHL] and radioimmunotherapy
More informationThe Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma
The Blood Cancer Twice As Likely To Affect African Americans: Multiple Myeloma 11 th Annual National Leadership Summit on Health Disparities Innovation Towards Reducing Disparities Congressional Black
More informationGraft Failure After HSCT
Graft Failure After HSCT Vanderson Rocha, MD, PhD Professor of Haematology- Oxford University Bone Marrow Transplant Unit- Sirio Libanes Hospital- Sao Paulo Scientific Director of Eurocord-Paris Clinical
More informationChapter 8. Summary, general discussion and future perspectives
Summary, general discussion and future perspectives 115 Summary Multiple Myeloma (MM) is characterized by a malignant proliferation of monoclonal plasma cells in the bone marrow, clinical presenting by
More informationMyeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants
Educational 2 Cord Blood Transplantation Myeloablative versus Reduced Intensity Conditioning Regimen Cord Blood Transplants William Arcese University of Rome Tor Vergata Rome Transplant Network 4th April
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationCord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Clofarabine in the treatment of relapsed acute myeloid leukaemia (AML) The application was for clofarabine to remain in
More informationHematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD
Hematopoietic Stem Cell Transplantation: Current Status and Future Directions RICHARD W. CHILDS M.D. NIH, BETHESDA MD Stem cell transplantation Autologous Autologous stem cell collection Freeze Stem Cells
More informationImmunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis
Immunoablative therapy with autologous hematopoietic stem cell transplantation in the treatment of poor risk multiple sclerosis T Kozák, P Lhotáková Department of Clinical Haematology, 3r d School of Medicine,
More informationStem Cell Transplantation in Adults
Recommendation Report Stem Cell Transplantation in Adults K. Imrie, R.B. Rumble, M. Crump, the Advisory Panel on Bone Marrow and Stem Cell Transplantation, and the Hematology Disease Site Group of Cancer
More informationGuidelines for the Management of Follicular Lymphoma
Guidelines for the Management of Follicular Lymphoma Scope The following guidance for first- and second-line therapy applies to follicular lymphoma histological grades 1, 2 and 3a according to the World
More informationMantle Cell Lymphoma Understanding Your Treatment Options
New Developments in Mantle Cell Lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Vice Chairman, Department
More informationBlood-Forming Stem Cell Transplants
Blood-Forming Stem Cell Transplants What are bone marrow and hematopoietic stem cells? Bone marrow is the soft, sponge-like material found inside bones. It contains immature cells known as hematopoietic
More informationDESCRIPTION/BACKGROUND
Original Issue Date (Created): August 23, 2004 Most Recent Review Date (Revised): Effective Date: October 21, 2008 July 1, 2009- RETIRED I. DESCRIPTION/BACKGROUND Hematopoietic Stem-Cell Transplantation
More informationNot for publication or presentation
MINUTES CIBMTR WORKING COMMITTEE FOR GVHD Orlando, Florida Thursday, February 25, 2010, 2:45 pm 4:45 pm Statisticians: Scientific Directors: Steven Pavletic MD, National Cancer Institute Telephone: 301-402-4899;
More informationCHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY
CHAPTER 26 LATE BREAKING DEVELOPMENTS: IMPACT OF ANTI-CD20 MONOCLONAL ANTIBODIES ON LYMPHOMA THERAPY 26.1 Introduction rituximab Subsequent to the completion of drafts for the guidelines earlier in 2004,
More informationStem Cell Transplantation In Patients with Fanconi Anemia
Stem Cell Transplantation In Patients with Fanconi Anemia FARF Annual Family Meeting 6/28/15 Casco, ME Parinda A. Mehta, M.D. Cincinnati Children s Hospital Medical Center Improvements in Unrelated Donor
More informationARTICLES AND BRIEF REPORTS
ARTICLES AND BRIEF REPORTS Stem Cell Transplantation Younger donor s age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic
More informationLong Term Low Dose Maintenance Chemotherapy in the Treatment of Acute Myeloid Leukemia
Long Term Low Dose Chemotherapy in the Treatment of Acute Myeloid Leukemia Murat TOMBULO LU*, Seçkin ÇA IRGAN* * Department of Hematology, Faculty of Medicine, Ege University, zmir, TURKEY ABSTRACT In
More informationCure of multiple myeloma more hype, less reality
(2006) 37, 1 18 & 2006 Nature Publishing Group All rights reserved 0268-3369/06 $30.00 www.nature.com/bmt REVIEW more hype, less reality P Hari 1, MC Pasquini 1 and DH Vesole 2 1 Medical College of Wisconsin,
More informationBone Marrow/Stem Cell Transplant
Blue Distinction Centers for Transplants Program Selection Criteria for 2010 Mid-Point Designations To qualify as a Blue Distinction Center for Transplants (), each facility must satisfy s quality based
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression
More informationMyeloablative conditioning regimens for the
ACUTE MYELOID LEUKEMIA What is the role of reduced-intensity transplantation in the treatment of older patients with AML? Stephen J. Forman 1 1 Department of Hematology and Hematopoietic Cell Transplantation,
More informationcancer cancer Hessamfar-Bonarek M et al. Int. J. Epidemiol. 2010;39:135-146
Hematopoietic Stem Cell Transplant in HIV- related lymphoma Song Zhao, MD PhD Hematology-Oncology Program University of Washington/FHCRC Underlying Causes of Death in HIV-infected Adults 2000 2005 cancer
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More informationAutologous Retransplantation for Patients With Recurrent Multiple Myeloma
Autologous Retransplantation for Patients With Recurrent Multiple Myeloma A Single-Center Experience with 200 Patients Leopold Sellner, MD 1 ; Christiane Heiss 2 ; Axel Benner 2 ; Marc S. Raab, MD 1 ;
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
More informationKEY WORDS: Autologous stem cell transplantation, Salvage, Myeloma INTRODUCTION
Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation Registry Gordon Cook,
More information2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders
UPDATE ECIL-4 2011 2011 Update on the ECIL-3 guidelines for EBV management in patients with leukemia and other hematological disorders Jan Styczynski, Hermann Einsele, Rafael de la Camara, Catherine Cordonnier,
More informationProtocol. Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia
Hematopoietic Stem Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 04/01/13 Next Review Date: 03/16 Preauthorization Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12,
More informationCurrent Multiple Myeloma Treatment Adapted From the NCCN Guidelines
Current Multiple Myeloma Treatment Adapted From the NCCN Guidelines Diagnosis Survival 3-5 yrs Survival
More informationMultiple Myeloma: Novel Agents. Robert A. Kyle, M.D. Germany June 28, 2008. Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida
Multiple Myeloma: Novel Agents Robert A. Kyle, M.D. Germany June 28, 2008 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Multiple Myeloma Untreated Initial Therapy Transplant eligible Multiple
More informationEBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 CHAPTER 20. HSCT for acute myeloid leukaemia in adults. R. Varaldo, F. Frassoni
EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 356 * CHAPTER 20 HSCT for acute myeloid leukaemia in adults R. Varaldo, F. Frassoni EBMT2008_1_21:EBMT2008 6-11-2008 9:22 Pagina 357 CHAPTER 20 AML in adults
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationREVIEW ARTICLE. Introduction
REVIEW ARTICLE Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the
More informationEvaluation of von Willebrand factor and Factor VIII levels in multiple myeloma patients treated with Thalidomide
chapter 7 Evaluation of von Willebrand factor and Factor VIII levels in multiple myeloma patients treated with Thalidomide A.M.W. van Marion* J.A. Auwerda* T. Lisman P. Sonneveld H.M. Lokhorst F.W.G. Leebeek
More informationShaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological
An update on the management of multiple myeloma and amyloidosis Shaji Kumar, M.D. Multiple Myeloma: Multiple myeloma (MM) is the second most common hematological malignancy in this country affecting nearly
More informationStem Cell Transplantation
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationLenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
More informationWhat is a Stem Cell Transplantation?
What is a Stem Cell Transplantation? Guest Expert: Stuart, MD Associate Professor, Medical Oncology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Drs. Ed and Ken. I am
More informationDisclosures. I have no disclosures.
Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer
More informationLEUCEMIA MIELOIDE ACUTA. A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova
LEUCEMIA MIELOIDE ACUTA A.M. Carella U.O.C. Ematologia IRCCS AOU San Martino IST, Genova Impact of mutational analysis in AML C. Thiede Optimal acute myeloid leukemia therapy in 2012 H. Dombret Acquired
More informationName of Policy: Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis
Name of Policy: Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis Policy #: 383 Latest Review Date: February 2015 Category: Surgery Policy Grade: A Background: As a general rule, benefits
More informationBMT CTN PROTOCOL 0202 VERSION 4.0. Study Co-Chairpersons Ginna Laport, M.D. 1 Robert Negrin, M.D. 1. Protocol Team
Autologous vs. Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients with Chemosensitive Follicular Non-Hodgkin s Lymphoma Beyond First Complete Response or First Partial
More informationHaematopoietic stem cell transplantation in Hong Kong
S C I E N T I F I C P A P E R Haematopoietic stem cell transplantation in Hong Kong Albert KW Lie WY Au Raymond Liang 李 國 維 區 永 仁 梁 憲 孫 The first case of haematopoietic stem cell transplant (HSCT) was
More informationNon-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma!"#$%&'()*+,-./0!1
Key words: Multiple myeloma; Myeloablative agents; Transplantation!!"#$! SY Ma AKW Lie WY Au CS Chim YL Kwong R Liang Hong Kong Med J 4;1:77-83 Division of Haematology and Oncology, Department of Medicine,
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 10/1/2014 Most Recent Review Date (Revised): 6/2/2015 Effective Date: 8/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More information